跳至主要内容
临床试验/NCT02025608
NCT02025608已完成4 期

Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome: AUTOREST, a Case-control Study and a Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week, Multicenter Study of 0.25mg Pramipexole vs. Placebo in Patients With RLS

Mauro Manconi2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2013年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Mauro Manconi
入组人数
20
试验地点
2
主要终点
Change in heart rate activations during sleep from baseline to 4 weeks

研究概览

简要总结

The purpose of this study is to explore whether patients with restless legs syndrome (RLS) differ from healthy subjects in daytime and night time autonomic function and cardiovascular risk markers and whether 4 week treatment with pramipexole affects autonomic function and cardiovascular risk markers in patients with RLS.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
30 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Pramipexole

Experimental

Pramipexole, 0.25 mg, daily for 4 weeks

干预措施: Pramipexole (Drug)

Placebo

Placebo Comparator

Placebo, daily for 4 weeks

干预措施: Placebo (Drug)

结局指标

主要结局

Change in heart rate activations during sleep from baseline to 4 weeks

时间窗: Baseline, Week 4

Number and amplitude of periodic leg movements during sleep (PLMS) and non-PLMS related heart rate activations during stable nocturnal sleep

次要结局

  • Change in baroreflex from baseline to 4 weeks(Baseline, Week 4)
  • Change in blood serum markers from baseline to 4 weeks(Baseline, Week 4)

研究者

发起方
Mauro Manconi
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Mauro Manconi

Dr. med.

Ospedale Regionale di Lugano

研究点 (2)

Loading locations...

相似试验